FibroBiologics, Inc Common Stock

Yahoo Finance • 17 days ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 28 days ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 2 months ago

FibroBiologics reports 1H results

* FibroBiologics press release [https://seekingalpha.com/pr/20185766-fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:FBLG [https://seekingalpha.com/symbol/FBLG]): 1H For the six months... Full story

Yahoo Finance • 2 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 2 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 3 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 3 months ago

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 4 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 4 months ago

FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 4 months ago

FibroBiologics announces CFO appointment

* FibroBiologics (NASDAQ:FBLG [https://seekingalpha.com/symbol/FBLG]) announced the appointment of Jason D. Davis, CPA, as chief financial officer, effective immediately.  * Davis most recently served as CFO of Virax Biolabs (VRAX [htt... Full story

Yahoo Finance • 5 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential c... Full story

Yahoo Finance • 6 months ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for c... Full story

Yahoo Finance • 6 months ago

FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt

HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges Biotechnologieunternehmen mit über 240 erteilten und angemeldeten Patenten für die En... Full story

Yahoo Finance • 6 months ago

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for c... Full story

Yahoo Finance • 6 months ago

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical tr... Full story

Yahoo Finance • 6 months ago

FibroBiologics Announces 2025 Annual Meeting of Stockholders

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 7 months ago

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 7 months ago

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now availa... Full story

Yahoo Finance • 7 months ago

Life Sciences Investor Forum Agenda Announced for March 13th

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Ca... Full story

Yahoo Finance • 7 months ago

FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an

Diese innovative Methode hat das Potenzial, neue Behandlungsmöglichkeiten für chronische Erkrankungen zu erschließen, die durch mitochondriale Dysregulation verursacht werden. HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics,... Full story